Merck (NYSE:MRK) recently announced positive Phase 1b clinical study results for its experimental Alzheimer's disease drug  MK-8931. This compound belongs to a broader class of experimental Alzheimer's treatments called BACE inhibitors, and AstraZeneca (NYSE:AZN) and Eli Lilly (NYSE:LLY) have also explored drugs in this class. In the following video, health-care analyst Max Macaluso discusses the latest results, why shares of Merck didn't move significantly on the news, and also takes a look at the broader BACE inhibitor space.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.